Overview

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct acting antiviral (DAA)-containing regimen.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin